



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Monday, December 01, 2008

SignalGene Incorporated

[View the current SignalGene Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/9539-SignalGene+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/9539-SignalGene+Incorporated.html>)

Contact Details:

8475 Christophe-Colomb Avenue Suite 1000

Montreal

Quebec

H2M 2N9

Canada

Tel: 514 850 2400

Fax: 514 850 2424

Email: michael.dennis@signalgene.com

Mission To be a leader in the application of genome-based information and technologies for the improved diagnosis and treatment of major human diseases.

Corporate Profile

SignalGene Inc. is a Montreal-based, publicly traded company (SGI: Montreal and Toronto Stock Exchange) dedicated to improving human health care through the application of scientific breakthroughs in human genetic research.

Created in 1996 as Algène Biotechnologies Corporation, SignalGene is strengthening its position by combining the expertise of research collaborators with enabling technologies, management depth and commercial focus. The Company pursues human genomics research for the development of high value products and services that lead to major improvement in the practice of medicine.

SignalGene's research activities focus on the identification of human genes and genes variants, which predict individual susceptibility to diseases and response to therapeutic drugs. This research also identifies novel targets for drug discovery.

Current research programs focus on five important human disorders, namely osteoporosis, breast cancer, psoriasis, obesity and Alzheimer's disease; and involve collaborations with leading biomedical and clinical scientists in Quebec university hospitals.

The Company's drug discovery strategy is based on a portfolio of proprietary nuclear receptor variants that are validated as potential drug targets for major human diseases.

Strategies for Sustainable Growth and Value Generation

To achieve its corporate objectives, SignalGene works with strategic partners to accelerate its own internal discovery programs and to generate revenue through license fees, milestone payments and future royalties. SignalGene also leverages its technologies and expertise to perform contract research to support its clients' discovery programs.

SignalGene aims to generate a strong expanding revenue stream by the marketing of genotyping services with a special focus on pharmacogenomics and genetic profiling assays.

Its evolving portfolio of proprietary genetic markers and drug targets for major human diseases is the foundation of SignalGene's ultimate objective, which is to develop and market diagnostic and therapeutic products.

Services

SignalGene offers pharmaceutical and biotech companies a broad range of services.

Integrated Genomics Platforms

? Clinical cohorts: ethical recruitment of patients and collection of genomic samples and clinical data

? Gene discovery: positional cloning, allele association

? Target validation: transgenic mice models, functional assays

? Bioinformatics: database mining, statistical data analysis

Genotyping Services

? Pharmacogenomics markers: e.g. DMEs, APOE4, etc.

? Disease markers: genetic profiling, susceptibility testing

? Custom genotyping

SignalGene exploits a robust high throughput technology platform in a quality-controlled environment that, as of the year 2000 meets GLP/GMP standards.

Discovery Programs

Our discovery programs lead to major breakthroughs in the identification of genetic markers of disease susceptibility and response to drug therapy, and provide novel targets for new drug development.

Recent Publications by SignalGene Incorporated:



- [In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenyl-naphthyl alkene ligands for the estrogen receptor.](#)

There is still a need for additional scaffolds to further explore tissue... 26th July, 2005

SignalGene Inc., 335 Laird Rd, Unit 2, Guelph, Ontario, Canada N1G 4P7.- Bioorg Med Chem. 2005 Mar 1;13(5):1819-28.

- [Predicting synthetic accessibility: application in drug discovery and development.](#)

The estimation and use of synthetic accessibility in the drug discovery... 17th September, 2004

SignalGene Inc., 335 Laird Road - Unit 2, Guelph, Ontario, N1G 4P7 Canada.- Mini Rev Med Chem. 2004 Aug;4(6):681-92.

- [De novo design, synthesis and evaluation of a non-steroidal diphenyl-naphthyl propylene ligand for the estrogen receptor.](#)

There is still a strong need for additional diversity and new chemical... 11th November, 2003

SignalGene Inc., 335 Laird Road, Unit 2, Guelph, Ontario, Canada N1G 4P7.- Bioorg Med Chem. 2003 Apr 3;11(7):1389-96.

- [De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor.](#)

Although there are many estrogen receptor antagonists with improved tissue... 9th May, 2003

SignalGene Inc., 335 Laird Road, Unit 2, Guelph, Ontario, Canada N1G 4T2.- J Med Chem. 2003 Apr 10;46(8):1408-18. ([DOI Direct Link](#))

- [Synthesis and evaluation of a novel nonsteroidal-specific endothelial cell proliferation inhibitor.](#)

The identification of agents with specific antiproliferative or cytostatic... 9th May, 2003

SignalGene Inc., Unit 2, 335 Laird Road, Guelph, Ontario N1G 4P7, Canada.- J Med Chem. 2003 Apr 10;46(8):1289-92. ([DOI Direct Link](#))

- [Coregulators of estrogen receptor action.](#)

The estrogen receptors are members of a large family of transcription... 6th May, 2003

Drug Discovery Unit, SignalGene Inc., Montreal, Canada.- Crit Rev Eukaryot Gene Expr. 2002;12(1):1-22.

- [Property distributions: differences between drugs, natural products, and molecules from combinatorial](#)

[chemistry.](#)

The differences between three different compound classes, natural... 8th April, 2003

SignalGene Inc., 335 Laird Road, Unit 2, Guelph, Ontario, N1G 4P7, Canada.- J Chem Inf Comput Sci. 2003 Jan-Feb;43(1):218-27. ([DOI Direct Link](#))



SignalGene Incorporated Patents:

- 6498024- [Subtractive amplification kit useful in the diagnosis of genetic disease mutation or variation](#)
- 6183963- [Detection of CYP1A1, CYP3A4, CYP2D6 and NAT2 variants by PCR-allele-specific oligonucleotide \(ASO\) assay](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

